Neprilysin inhibitors
AssigneeTheravance Biopharma R&D IP, LLC
InventorsRoland Gendron, Melissa Fleury, Adam D. Hughes
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Claims21
1-28. (canceled)
A method of treating a disease mediated at least in part by neprilysin in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from —OR7 and —NR8R9;
- R2 is selected from H and —P(O)(OH)2;
- X is —C1-9heteroaryl;
- R3 is absent or is selected from H;
- halo;
- —C0-5alkylene-OH;
- —NH2;
- —C1-6alkyl;
- —CF3;
- —C3-7cycloalkyl;
- —C0-2alkylene-O—C1-6alkyl;
- —C(O)R20;
- —C0-1alkylene-COOR21;
- —C(O)NR22R23;
- —NHC(O)R24;
- ═O;
- —NO2;
- —C(CH3)═N(OH);
- phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl;
- naphthalenyl;
- pyridinyl;
- pyrazinyl;
- pyrazolyl, optionally substituted with methyl;
- thiophenyl, optionally substituted with methyl or halo;
- furanyl;
- and —CH2-morpholinyl;
- wherein R3, when present, is attached to a carbon atom;
- R4 is absent or is selected from H;
- —OH;
- —C1-6alkyl;
- —C1-2alkylene-COOR35;
- —CH2OC(O)CH(R36)NH2;
- —OCH2OC(O)CH(R36)NH2;
- —OCH2OC(O)CH3;
- —CH2OP(O)(OH)2;
- —CH2CH(OH)CH2OH;
- —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl;
- pyridinyl;
- and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3;
- wherein R4, when present, is attached to a carbon or nitrogen atom;
- a is 0 or 1;
- R5 is selected from halo, —CH3, —CF3, and —CN;
- b is 0 or an integer from 1 to 3;
- each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
- R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
- R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
- R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16;
- R15 and R16 are independently selected from H and —C1-4alkyl;
- R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
- R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
- R20 is selected from H and —C1-6alkyl;
- R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
- R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl;
- or
- R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
- R24 is selected from —C1-6alkyl;
- —C0-1alkylene-O—C1-6alkyl;
- phenyl, optionally substituted with halo or —OCH3;
- and —C1-9heteroaryl;
- and
- R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
- wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms;
- and
- wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.
A method of inhibiting activity of a neprilysin enzyme, comprising contacting the neprilysin enzyme with a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from —OR7 and —NR8R9;
- R2 is selected from H and —P(O)(OH)2;
- X is —C1-9heteroaryl;
- R3 is absent or is selected from H;
- halo;
- —C0-5alkylene-OH;
- —NH2;
- —C1-6alkyl;
- —CF3;
- —C3-7cycloalkyl;
- —C0-2alkylene-O—C1-6alkyl;
- —C(O)R20;
- —C0-1alkylene-COOR21;
- —C(O)NR22R23;
- —NHC(O)R24;
- ═O;
- —NO2;
- —C(CH3)═N(OH);
- phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl;
- naphthalenyl;
- pyridinyl;
- pyrazinyl;
- pyrazolyl, optionally substituted with methyl;
- thiophenyl, optionally substituted with methyl or halo;
- furanyl;
- and —CH2-morpholinyl;
- wherein R3, when present, is attached to a carbon atom;
- R4 is absent or is selected from H;
- —OH;
- —C1-6alkyl;
- —C1-2alkylene-COOR35;
- —CH2OC(O)CH(R36)N-2;
- —OCH2OC(O)CH(R36)N-2;
- —OCH2OC(O)CH3;
- —CH2OP(O)(OH)2;
- —CH2CH(OH)CH2OH;
- —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl;
- pyridinyl;
- and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3;
- wherein R4, when present, is attached to a carbon or nitrogen atom;
- a is 0 or 1;
- R5 is selected from halo, —CH3, —CF3, and —CN;
- b is 0 or an integer from 1 to 3;
- each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
- R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
- R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
- R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16,
- R15 and R16 are independently selected from H and —C1-4alkyl;
- R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
- R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
- R20 is selected from H and —C1-6alkyl;
- R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
- R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl;
- or
- R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
- R24 is selected from —C1-6alkyl;
- —C0-1alkylene-O—C1-6alkyl;
- phenyl, optionally substituted with halo or —OCH3;
- and —C1-9heteroaryl;
- and
- R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
- wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms;
- and
- wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.
A method of treating hypertension, heart failure, or renal disease in a subject in need thereof, comprising administering to the subject an AT1 receptor antagonist and an effective amount of a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from —OR7 and —NR8R9;
- R2 is selected from H and —P(O)(OH)2;
- X is —C1-9heteroaryl;
- R3 is absent or is selected from H;
- halo;
- —C0-5alkylene-OH;
- —NH2;
- —C1-6alkyl;
- —CF3;
- —C3-7cycloalkyl;
- —C0-2alkylene-O—C1-6alkyl;
- —C(O)R20;
- —C0-1alkylene-COOR21;
- —C(O)NR22R23;
- —NHC(O)R24;
- ═O;
- —NO2;
- —C(CH3)═N(OH);
- phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl;
- naphthalenyl;
- pyridinyl;
- pyrazinyl;
- pyrazolyl, optionally substituted with methyl;
- thiophenyl, optionally substituted with methyl or halo;
- furanyl;
- and —CH2-morpholinyl;
- wherein R3, when present, is attached to a carbon atom;
- R4 is absent or is selected from H;
- —OH;
- —C1-6alkyl;
- —C1-2alkylene-COOR35;
- —CH2OC(O)CH(R36)N-2;
- —OCH2OC(O)CH(R36)N-2;
- —OCH2OC(O)CH3;
- —CH2OP(O)(OH)2;
- —CH2CH(OH)CH2OH;
- —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl;
- pyridinyl;
- and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3;
- wherein R4, when present, is attached to a carbon or nitrogen atom;
- a is 0 or 1;
- R5 is selected from halo, —CH3, —CF3, and —CN;
- b is 0 or an integer from 1 to 3;
- each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
- R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
- R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
- R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16,
- R15 and R16 are independently selected from H and —C1-4alkyl;
- R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
- R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
- R20 is selected from H and —C1-6alkyl;
- R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl;
- or
- R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
- R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
- R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
- R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl;
- or
- R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
- R24 is selected from —C1-6alkyl;
- —C0-1alkylene-O—C1-6alkyl;
- phenyl, optionally substituted with halo or —OCH3;
- and —C1-9heteroaryl;
- and
- R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
- wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms;
- and
- wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.
Dependencies are inferred from the claim text.